IC50: 0.76 nM for LATS1, 0.52 nM for LATS2[1]
VT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the
[1]. Ma S, et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022 Feb 25;13(1):1061.
















